Renaissance Technologies LLC Has $2.17 Million Stake in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Renaissance Technologies cut its Prestige Consumer Healthcare stake by 62% in the first quarter, selling 59,900 shares and retaining 36,702 shares valued at approximately $2.17 million. Institutional investors collectively own 99.95% of PBH.
• Prestige Consumer Healthcare reported quarterly EPS of $0.98, exceeding estimates of $0.89, while revenue rose 6.5% year over year to $265.71 million. The company issued fiscal 2027 EPS guidance of $4.55–$4.65.
• Analyst sentiment is mixed, with two Buy, two Hold, and two Sell ratings; the stock carries an overall “Hold” rating and an average price target of $70.75. PBH shares recently traded at $52.79, down 3.8%.

Renaissance Technologies LLC reduced its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 62.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,702 shares of the company's stock after selling 59,900 shares during the quarter. Renaissance Technologies LLC owned approximately 0.08% of Prestige Consumer Healthcare worth $2,175,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PBH. Dimensional Fund Advisors LP grew its holdings in shares of Prestige Consumer Healthcare by 3.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,672,777 shares of the company's stock valued at $158,414,000 after acquiring an additional 91,710 shares in the last quarter. State Street Corp raised its holdings in shares of Prestige Consumer Healthcare by 1.4% during the fourth quarter. State Street Corp now owns 1,992,497 shares of the company's stock worth $122,917,000 after acquiring an additional 27,721 shares in the last quarter. Morgan Stanley boosted its position in Prestige Consumer Healthcare by 6.3% during the fourth quarter. Morgan Stanley now owns 1,202,927 shares of the company's stock valued at $74,209,000 after purchasing an additional 71,078 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Prestige Consumer Healthcare by 5.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 738,654 shares of the company's stock valued at $45,568,000 after purchasing an additional 35,126 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in Prestige Consumer Healthcare by 19.1% in the second quarter. Bank of America Corp DE now owns 721,371 shares of the company's stock valued at $57,601,000 after purchasing an additional 115,459 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Trading Down 3.8%

Shares of PBH stock opened at $52.79 on Tuesday. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $71.07. The firm's fifty day simple moving average is $48.96 and its 200 day simple moving average is $55.91. The firm has a market capitalization of $2.50 billion, a P/E ratio of 14.79, a price-to-earnings-growth ratio of 1.70 and a beta of 0.34. The company has a current ratio of 3.23, a quick ratio of 1.99 and a debt-to-equity ratio of 1.06.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $0.09. The firm had revenue of $265.71 million during the quarter, compared to the consensus estimate of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business's revenue was up 6.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.6 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on PBH shares. Weiss Ratings lowered Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, June 25th. Canaccord Genuity Group dropped their price objective on Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating on the stock in a report on Friday, May 15th. Oppenheimer lowered shares of Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 14th. Finally, Zacks Research cut shares of Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $70.75.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source